Details

Autor(en) / Beteiligte

• Greiner, J
• Dohner, H
• Schmitt, M

Titel

Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens

Ist Teil von

• Haematologica (Roma), 2006-12, Vol.91 (12), p.1653-1661

Ort / Verlag

Pavia: Haematologica

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• Tumor Immunology Group, Dept. of Internal Medicine III, Robert-Koch-Str. 8 University of Ulm, 89081 Ulm, Germany. Targeted immunotherapies require the identification and characterization of appropriate antigen structures. Initially, T-cell based cancer vaccines were designed for patients with solid tumors after the definition of suitable tumor-associated antigens. Several immunological and even clinical responses prompted researchers and clinicians to extend the spectrum of cancer vaccines towards hematologic malignancies such as acute myeloid leukemia (AML). Only 20-40% of all patients with AML achieve a disease-free survival of more than 5 years. The graft-versus-leukemia (GVL) effect observed after allogeneic stem cell transplantation and donor lymphocyte infusions strongly suggests that T lymphocytes play a major role in the rejection of leukemic cells. Therefore, immunotherapy directed against leukemia-associated antigens might elicit specific immune responses that could eliminate minimal residual disease after chemotherapy, or enhance the GVL effect after hematopoietic stem cell transplantation. This review summarizes hitherto identified and characterized LAA as targets for T-cell-based immunotherapies. Current clinical peptide vaccination trials targeting different epitopes of the Wilms' tumor gene 1 (WT1), the proteinase-3 derived epitope peptide (PR1) and the receptor for hyaluronic acid mediated motility (RHAMM/CD168)-derived epitope R3 are reviewed, and perspectives but also limitations of immunotherapeutic approaches for AML patients are discussed.